Moderna amended its Ares Capital credit agreement, cutting term loan margins by 0.75 percentage points and extending maturity from November 24, 2030 to November 24, 2031.
MRNA · Moderna, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Moderna agreed that Chief Legal Officer Shannon Thyme Klinger will retire by March 31, 2027, with $1,628,300 in severance, COBRA support through September 30, 2028, and potential litigation payments of $2,500,000 and up to $5,500,000.
Moderna raised its 2026 revenue growth outlook to 15% to 25% from up to 10%. Its phase 3 melanoma therapy with pembrolizumab reduced recurrence or death risk by 42%, while quarterly revenue reached $1.3 billion.
Moderna reported revenue of $1,313 million and net income of $162 million for the quarter ended September 30, 2026. Nine-month net loss was $(1,963) million, and operating activities used $(2,715) million of cash.
Moderna reported third-quarter revenue of $1.3 billion and net income of $162 million, raised its 2026 revenue growth outlook to 15%–25%, and expects year-end cash and investments of approximately $8.1 billion to $8.3 billion.
Moderna appointed Juan Andres Chief Operating Officer effective October 5, 2026, to lead manufacturing and report to Stéphane Bancel. Jerh Collins will retire as Chief Technical Operations and Quality Officer.